Tmax, ke and t1/2 in fully replicate design of HVD [General Sta­tis­tics]

posted by Ken Peh – Malaysia, 2013-05-21 21:24 (4766 d 17:02 ago) – Posting: # 10612
Views: 5,640

Dear All,

When we run a fully replicate design for highly variable drug, may I know how elimination rate constant (ke) and elimination half-life (t1/2) are analyzed statistically ? Same as for AUC ??

What about Tmax ? As Tmax is analyzed statistically using non-parametric test for 2-way crossover design (2x2), I presumed this parameter should also be analyzed the same way for fully replicate design (2x4). The only difference is taking the average of Tmax of test and reference product.

Appreciate if could kindly comment on the above.

Thank you.

Regards,
Ken

Complete thread:

UA Flag
Activity
 Admin contact
23,653 posts in 4,991 threads, 1,570 registered users;
272 visitors (0 registered, 272 guests [including 16 identified bots]).
Forum time: 14:27 CEST (Europe/Vienna)

The epistemological value of probability theory is based on the fact
that chance phenomena, considered collectively and on a grand scale,
create non-random regularity.    Andrey Kolmogorov

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5